Seroprevalence of Bactericidal, Specific IgG Antibodies and Incidence of Meningitis Due to Group A Neisseria meningitidis by Age in Burkina Faso 2008

We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one Jg. 8; H. 2; S. e55486
Hauptverfasser:	Trotter, Caroline L., Yaro, Seydou, Njanpop-Lafourcade, Berthe-Marie, Drabo, Aly, Kroman, Sita S., Idohou, Regina S., Sanou, Oumarou, Bowen, Leah, Findlow, Helen, Diagbouga, Serge, Gessner, Bradford D., Borrow, Ray, Mueller, Judith E.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Public Library of Science 14.02.2013 Public Library of Science (PLoS)
Schlagworte:	Adolescent Adult Age Antibodies Biology Burkina Faso - epidemiology Child Child, Preschool Disease Epidemics Epidemiology Family medical history Female Genotype & phenotype Humans Immunity Immunoglobulin G Immunoglobulin G - blood Immunoglobulin G - immunology Immunoglobulins Incidence Infant Laboratories Life Sciences Male Medicine Meningitis Meningitis, Meningococcal - blood Meningitis, Meningococcal - epidemiology Meningitis, Meningococcal - immunology Middle Aged Neisseria meningitidis Neisseria meningitidis, Serogroup A - immunology Neisseria meningitidis, Serogroup A - isolation & purification Santé publique et épidémiologie Seroepidemiologic Studies Serology Serum Bactericidal Antibody Assay Set theory Studies Vaccines Young Adult Burkina Faso United Kingdom > UK France Neisseria meningitidis serogroup A (NmA) Immunity Burkina Faso
ISSN:	1932-6203, 1932-6203
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We investigated serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso before the introduction of NmA conjugate vaccine. We collected blood from a representative sample (N = 1022) of Bobo-Dioulasso residents. Sera were evaluated for serum bactericidal antibody (SBA) activity against NmA strains of immunotype L11 (F8238) and L10 (3125) and NmA-specific IgG. Seroprevalence was compared to the age-specific NmA meningitis incidence in Bobo-Dioulasso during March 2007-February 2008. Meningococcal carriage was evaluated in a subset (N = 538). Geometric mean titres (GMT)/concentrations (GMC) of SBA and NmA-specific IgG increased with age, peaking around age 20 years. Overall, 70% of our sample had NmA-specific IgG ≥2 ug/mL. Meningitis incidence was highest in those aged <6 months and 5-19 years. No NmA carriers were found. Compared to the reference strain SBA, GMTs were higher against a locally isolated strain and around 40-fold lower against Dutch strain 3125. This study provides estimates of natural immunity to NmA, according to a variety of antibody measures, which will be helpful in ascertaining antibody persistence after MenAfriVac™ introduction. Age-specific seroprevalence of reference strain SBA titres most likely reflects exposure to meningococci and consecutive reactive immunity. We could not define any serological correlate of protection.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Obtained funding for the study: CLT JEM RB SY. Approved final manuscript: CLT SY BMNL AD SSK OS LB HF SD BDG RB JEM. Conceived and designed the experiments: CLT JEM RB SY. Performed the experiments: JEM SY B-MN-L AD SSK RSI OS HF SD RB. Analyzed the data: CLT JEM LB. Wrote the paper: CLT JEM RB BDG. Competing Interests: BL, SSK, OS, RSI, and BDG work, and JEM until recently worked, for the Agence de Médecine Préventive, which receives unrestricted support from Sanofi Pasteur as well as grant specific support from Sanofi Pasteur, GlaxoSmithKline, Pfizer, and Merck. RB and HF have performed contract research on behalf of the Health Protection Agency, funded by Pfizer, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Sanofi Pasteur MSD, Alexion Pharmaceuticals Inc, and Merck. All other authors declare no conflicts of interest. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0055486